Skip to main content
. Author manuscript; available in PMC: 2013 Nov 21.
Published in final edited form as: Clin Cancer Res. 2012 May 1;18(9):10.1158/1078-0432.CCR-11-3167. doi: 10.1158/1078-0432.CCR-11-3167

Figure 1.

Figure 1

Saracatinib effects on tumor growth in colorectal cancer explants. A, seventeen colorectal cancer explants were treated with saracatinib 50 mg/kg/d by oral gavage for 28 days. Tumor size was evaluated twice per week by caliper measurements by the formula: tumor volume = (length × width2) × 0.52. TGI was calculated by relative tumor growth of treated mice divided by relative tumor growth of control mice × 100. Cases with a TGI < 50% were considered sensitive, TGI > 50% were considered resistant to saracatinib. Two xenografts (CRC007 and CRC040) were sensitive to saracatinib (TGI ≤ 50%) and 15 xenografts were resistant to saracatinib (TGI > 50%). Columns, mean (n = 8–10 tumors per group); bars, SE; and *, significance (P < 0.05) compared with vehicle-treated tumors. Mutational status of PIK3CA, PTEN, KRAS, APC, CTNNB1, and p53 are shown for each explant. Mutations in the PIK3CA gene were identified in CRC007 [3′ UTR; (c.*19T>C)], CRC040 (E542K), CRC042 [3′ UTR; (c.*19T>C)], and CRC020 (E542G). B, the relationship between PIK3CA mutation and saracatinib effects (TGI) in colorectal cancer explants. A significant association (P = 0.0157) between PIK3CA mutants and sensitivity was identified. CRC, colorectal cancer; WT, wild-type.